A Study to Assess the Impact of Speed and Site of Subcutaneous Injection on Pain, Tolerability, Safety, and Pharmacokinetics of Gantenerumab in Healthy Participants
A Single-Center, Randomized, Open-Label, Parallel-Group, Placebo-Controlled, Cross-Over Study To Investigate the Impact of Speed of Injection and Site of Injection on Pain, Tolerability, Safety, and Pharmacokinetics Following Subcutaneous Administration of Gantenerumab in Healthy Volunteers
Sponsor: Hoffmann-La Roche
Listed as NCT02882009, this PHASE1 trial focuses on Healthy Volunteer and remains completed. Sponsored by Hoffmann-La Roche, it has been updated 9 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jul 2019 — Jan 2021 [monthly]
Completed PHASE1
-
Jul 2018 — Jul 2019 [monthly]
Completed PHASE1
▶ Show 4 earlier versions
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE1
-
Jul 2017 — Jun 2018 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Feb 2017 — Jul 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Aug 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .